This is in line with recent data in 30 patients with colorectal cancer, suggesting that Apelin expression may represent a predictive biomarker for bevacizumab unresponsiveness (Zuurbier et al, 2017), independently confirming our results in human patients. Here, APLN is linked to colorectal cancer.